Canada Spends Logo

Explore our Budget 2026 analysis

Contribution: Industrial Research Assistance Program

Evolved Therapeutics Inc.

$450,000.00

RNAinsight™: a high-throughput functional screen that measures target knockdown to identify effective antibody-oligonucleotide conjugate (AOC) delivery antibodies

FY 2026-27 · 2026-08-01

Summary
The project aims to develop and quantify RNAinsight™, a high-throughput screen platform that measures knockdown directly via a turn-on reporter, to identify effective antibody-oligonucleotide conjugate (AOC) delivery antibodies.
Program
Industrial Research Assistance Program
Location
Vancouver|Vancouver, British Columbia, Canada
Recipient Type
For-profit organization
Business Number
725243406
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions

As published

Agreement End Date
2027-08-31
Agreement Number
1045812
Agreement Start Date
2026-08-01
Agreement Title
RNAinsight™: a high-throughput functional screen that measures target knockdown to identify effective antibody-oligonucleotide conjugate (AOC) delivery antibodies
Agreement Title (French)
RNAinsight™ : un examen fonctionnel à haut débit qui mesure l’inhibition de la cible afin d’identifier des anticorps efficaces pour l’administration de conjugués anticorps-oligonucléotides (AOC)
Agreement Type
Contribution
Agreement Value
$450,000.00
Amendment Number
0
Coverage
Industrial Research Assistance Program projects stimulate wealth creation for Canada through technological innovation and strengthen Canadian innovation ecosystem by creating new industrial capacity. | Les projets du Programme d'aide à la recherche industrielle favorisent la création de richesse au Canada grâce à l'innovation technologique et renforcent l'écosystème canadien de l'innovation en créant de nouvelles capacités industrielles.
Description
The project aims to develop and quantify RNAinsight™, a high-throughput screen platform that measures knockdown directly via a turn-on reporter, to identify effective antibody-oligonucleotide conjugate (AOC) delivery antibodies.
Description (French)
Le projet vise à développer et à quantifier RNAinsight™, une plateforme d’examen à haut débit qui mesure directement l’inhibition via un rapporteur « turn-on », afin d’identifier des anticorps efficaces pour l’administration de conjugués anticorps-oligonucléotides (AOC).
Expected Results
The expected results and outcomes of NRC Industrial Research Assistance Program is focused on growing small and medium-sized enterprises (SMEs) through innovation and wealth creation for Canada.
Expected Results (French)
Les résultats attendus du Programme d’aide à la recherche industrielle du CNRC sont axés sur la croissance des petites et moyennes entreprises (PME) grâce à l’innovation et à la création de richesse pour le Canada.
Federal Riding
Vancouver Quadra
Federal Riding (French)
Vancouver Quadra
Federal Riding Number
59040
NAICS Code
325410
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program
Program Name (French)
Programme d’aide à la recherche industrielle
Program Purpose
The purpose of Industrial Research Assistance Program Contributions to Firms is to provide support that assists small and medium-sized enterprises (SMEs) to advance their innovation knowledge and ability to innovate, grow through innovation and stimulate wealth creation for Canada.
Program Purpose (French)
Les contributions versées aux entreprises en vertu du Programme d’aide à la recherche industrielle ont pour objectif d’apporter un soutien aux petites et moyennes entreprises (PME) afin qu’elles puissent approfondir leurs connaissances en matière d’innovation et renforcer leur capacité d’innovation, de croissance et de création de richesse pour le Canada.
Recipient Business Number
725243406
Recipient City
Vancouver|Vancouver
Recipient Country
CA
Recipient Legal Name
Evolved Therapeutics Inc.
Recipient Postal Code
V6T 1Z3
Recipient Province or Territory
BC
Recipient Type
F
Reference Number
172-2026-2027-Q2-1045812